HCA Healthcare, Inc. (NYSE:HCA) Shares Bought by Two Sigma Investments LP

Two Sigma Investments LP increased its position in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 12,016.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 467,437 shares of the company's stock after buying an additional 463,579 shares during the quarter. Two Sigma Investments LP owned about 0.18% of HCA Healthcare worth $140,301,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HCA. Barclays PLC increased its position in HCA Healthcare by 22.3% in the 3rd quarter. Barclays PLC now owns 571,975 shares of the company's stock valued at $232,467,000 after acquiring an additional 104,409 shares during the period. Merit Financial Group LLC raised its stake in shares of HCA Healthcare by 137.7% during the fourth quarter. Merit Financial Group LLC now owns 1,569 shares of the company's stock worth $471,000 after purchasing an additional 909 shares during the last quarter. Arkadios Wealth Advisors grew its position in HCA Healthcare by 46.9% in the 4th quarter. Arkadios Wealth Advisors now owns 3,435 shares of the company's stock valued at $1,031,000 after buying an additional 1,096 shares during the last quarter. Clarius Group LLC raised its position in HCA Healthcare by 19.1% during the 4th quarter. Clarius Group LLC now owns 1,540 shares of the company's stock worth $462,000 after buying an additional 247 shares during the last quarter. Finally, Clear Harbor Asset Management LLC acquired a new position in shares of HCA Healthcare during the fourth quarter worth about $320,000. Hedge funds and other institutional investors own 62.73% of the company's stock.

HCA Healthcare Price Performance

NYSE:HCA opened at $387.49 on Monday. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07. The firm has a market cap of $93.22 billion, a price-to-earnings ratio of 17.64, a price-to-earnings-growth ratio of 1.10 and a beta of 1.46. The company's 50-day moving average is $340.72 and its two-hundred day moving average is $328.30. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $417.14.

HCA Healthcare (NYSE:HCA - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $6.45 EPS for the quarter, beating analysts' consensus estimates of $5.75 by $0.70. The business had revenue of $18.32 billion during the quarter, compared to the consensus estimate of $18.26 billion. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. The business's revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.36 earnings per share. Research analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 16th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Monday, June 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.74%. HCA Healthcare's dividend payout ratio (DPR) is presently 12.81%.

Insider Buying and Selling

In other HCA Healthcare news, COO Jon M. Foster sold 15,698 shares of HCA Healthcare stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $369.32, for a total transaction of $5,797,585.36. Following the transaction, the chief operating officer now directly owns 12,646 shares of the company's stock, valued at $4,670,420.72. The trade was a 55.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on HCA. Royal Bank of Canada lowered their price objective on HCA Healthcare from $384.00 to $376.00 and set an "outperform" rating on the stock in a report on Monday, April 28th. StockNews.com upgraded HCA Healthcare from a "hold" rating to a "buy" rating in a research report on Monday, April 28th. Barclays lowered their price target on shares of HCA Healthcare from $392.00 to $366.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Baird R W downgraded shares of HCA Healthcare from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 15th. Finally, Robert W. Baird reiterated a "neutral" rating and set a $336.00 price target (down from $396.00) on shares of HCA Healthcare in a research report on Tuesday, April 15th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $381.13.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.